Description
MA
I
CP
DW
PGx
PV
B
MA
Mechanisms of Action
biochemical interactions to produce intended pharmacological effects. Curated from scientific literature and post-marketing package inserts. Source: ChEMBL
Mechanism of Action | Target Name | Human targets | References |
|---|---|---|---|
1 - 10 of 10
I
Indications
Investigational and approved indications for curated from clinical trial records and post-marketing package inserts. Source: ChEMBL.
Indication | Therapeutic Areas | Max Phase | Source |
|---|---|---|---|
1 - 10 of 10
CP
Clinical Precedence
Clinical trial records, including curated indication and mechanism of action for . Source: ChEMBL.
Disease information | Target information | Clinical trials information | |||
|---|---|---|---|---|---|
Disease | Symbol | Name | Phase | Status | Source |
1 - 0 of 0
DW
Drug Warnings
Manually curated withdrawn and black box warnings for . Source: ChEMBL
Warning type | Adverse event | ChEMBL warning class | Country / region | Year | References |
|---|---|---|---|---|---|
1 - 10 of 10
PGx
Pharmacogenetics
Genetic variants that are associated with the response to Source: PharmGKB.
Gene | rsID | Star Allele | Genotype ID? | Variant Consequence | Drug Response Phenotype | Drug Response Category | Direct Drug Target | Confidence Level? | Source | Literature |
|---|---|---|---|---|---|---|---|---|---|---|
1 - 10 of 10
PV
Pharmacovigilance
Significant post-marketing adverse events for estimated from reports submitted to the FDA Adverse Event Reporting database by healthcare professionals. Source: Open Targets.
